RNF130 protects against pulmonary fibrosis through suppressing aerobic glycolysis by mediating c-myc ubiquitination
International Immunopharmacology · 2023-04 · 117 · 109985
DOI: 10.1016/j.intimp.2023.109985 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023-04. Verfasst von Jinming Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, …. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Proto-Oncogene Proteins c-myc, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal disease,characterized by an excessive accumulation of extracellular matrix (ECM) proteins in response to chronic lung injury. Current evidence suggests that metabolic reprogramming is always accompanied by myofibroblast activation in IPFof whichthe underlying mechanisms remain unclear. Ring finger protein 130 (RNF130), was demonstrated involved in multiple diseases. However, whether RNF130 plays a critical role in the pathogenesis of IPF needs to be clarified. METHODS: We first investigated the expression of RNF130 in pulmonary fibrosis in vivo and in vitro. We then observed the effect and explored the molecular mechanism of RNF130 on the transition of fibroblast to myofibroblast and aerobic glycolysis. Further, we assessed the effects of adeno-associated virus (AAV)-induced RNF130 overexpression in the pulmonary fibrosis model, conducting pulmonary function, assessment of collagen depositionusing the hydroxyproline assay, and biochemical and histopathological analyses. RESULTS: We found that RNF130 was down-regulated in lung tissues of mice with bleomycin-induced pulmonary fibrosis and lung fibroblasts treated with transforming growth factor-β1 (TGF-β1). Then we demonstrated that RNF130 inhibitedthe transition of fibroblast to myofibroblast by suppressing aerobic glycolysis. Mechanistically, we revealed that RNF130 promotedc-myc ubiquitination and degradation, while c-myc overexpression reverses the inhibitory effects of RNF130. Importantly, pulmonary function, collagen deposition and fibroblast differentiation were significantly alleviated in adeno-associated virus serotype (AAV)6-RNF130 treated mice, which further validated the contribution of RNF130/c-myc signaling axis in pulmonary fibrosis pathological process. CONCLUSIONS: In summary, RNF130 participates in the pathogenesis of pulmonary fibrosis by inhibiting the transition of fibroblast to myofibroblast and aerobic glycolysis through promoting c-myc ubiquitination and degradation. Targeting RNF130-c-myc axismightrepresent a promising strategy to alleviate the progression of IPF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Occupational Health and Medicine, School of Public Health, Southern Medical University, Guangzhou, China.
- Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China. Electronic address: hxkc@smu.edu.cn.
- Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China. Electronic address: dhm@smu.edu.cn.
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
Zitieren
APA
Zhang, J., Chen, W., Du, J., Chu, L., Zhou, Z., Zhong, W., Liu, D., Huang, H., Huang, Y., Qiao, Y., Meng, X., Zou, F., Cai, S., & Dong, H. (2023). RNF130 protects against pulmonary fibrosis through suppressing aerobic glycolysis by mediating c-myc ubiquitination. International Immunopharmacology, 117, 109985. https://doi.org/10.1016/j.intimp.2023.109985
Vancouver
Zhang J, Chen W, Du J, Chu L, Zhou Z, Zhong W, et al. RNF130 protects against pulmonary fibrosis through suppressing aerobic glycolysis by mediating c-myc ubiquitination. International Immunopharmacology. 2023;117:109985. doi:10.1016/j.intimp.2023.109985
BibTeX
@article{Zhang2023,
author = {Zhang, Jinming and Chen, Weimou and Du, Jiangzhou and Chu, Lanhe and Zhou, Zili and Zhong, Wenshan and Liu, Dongyu and Huang, Haohua and Huang, Yi and Qiao, Yujie and Meng, Xiaojing and Zou, Fei and Cai, Shaoxi and Dong, Hangming},
title = {RNF130 protects against pulmonary fibrosis through suppressing aerobic glycolysis by mediating c-myc ubiquitination},
journal = {International Immunopharmacology},
year = {2023},
volume = {117},
pages = {109985},
doi = {10.1016/j.intimp.2023.109985}
}
EUVIMED